Completed PHASE1 INTERVENTIONAL 4-arm NCT01748838

Phase 1 Study Assessing the Safety and Tolerability of CTX-4430

A Phase I Randomised, Double-Blind, Placebo-Controlled, Ascending Single & Repeat-Dose Study of Safety, Tolerability & Pharmacokinetics of CTX-4430 When Administered Orally to Healthy Adult Subjects

Sponsor: CPR Pharma Services Pty Ltd, Australia

Conditions Pulmonary Inflammation

Interventions CTX-4430 Mannitol Placebo

Updated 5 times since 2017 Last updated: Sep 9, 2013 Started: Dec 31, 2012 Primary completion: Jul 31, 2013 Completion: Sep 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Pulmonary Inflammation and is currently completed. CPR Pharma Services Pty Ltd, Australia leads this study, which shows 5 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Dec 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CPR Pharma Services Pty Ltd, Australia
Celtaxsys, Inc.
Clinical Network Services
Linear Clinical Research

Data source: Celtaxsys, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nedlands, Australia